By Fineline Cube 
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) released its financial results for the first half of 2025, reporting a revenue of RMB 950 million, marking a 31.3% year-on-year decrease. The company recorded a loss of RMB 145 million during the period.
Product Launches and Commercialization
Despite the revenue decline, Kelun-Biotech achieved marketing authorization for sacituzumab, tagitanlimab, and cetuximab N01, and initiated their commercialization. Trastuzumab botidotin is slated for launch in the Chinese market in the second half of 2025, with an New Drug Application (NDA) filing expected for A400. Total commercial sales for the first half of 2025 reached RMB 310 million, with sacituzumab contributing 97.6% of this total. The company demonstrated efficient cash flow management with all drug sales receivables collected within payment terms.
Global Strategic Partnerships
Kelun-Biotech’s pipeline and drug development capabilities have garnered recognition from global strategic partners. The company has entered into licensing and collaboration agreements with Merck & Co. for the development of several antibody-drug conjugate (ADC) assets for cancer treatment. Notably, Kelun is the first Chinese company to license an internally discovered and developed ADC candidate to a top ten biopharmaceutical multinational company. Additionally, the company has established collaboration and licensing agreements with other partners, including Ellipses Pharma and Windward Bio.-Fineline Info & Tech